Most Read Articles
29 Mar 2020
Targeting a low-density lipoprotein cholesterol level <70 mg/dL following an ischaemic stroke of atherosclerotic origin helps to avoid one in four subsequent major vascular events without increasing the risk of intracranial haemorrhage over about 5 years of follow-up, according to data from the Treat Stroke to Target trial.
Pearl Toh, 12 Sep 2020
Early initiation of rhythm-control therapy led to a significantly reduced risk of major adverse cardiovascular (CV) outcomes compared with usual care (typically rate control) in patients with newly diagnosed atrial fibrillation (AF) at risk of stroke, reveals the EAST-AFNET 4* trial presented at ESC 2020.
01 Feb 2020
High-intensity statin therapy appears to be seeing increased use in patients with acute coronary syndrome and leads to better lipid control, according to a recent Thailand study.
18 Apr 2020
Statins appear to be useful as a primary prevention treatment in older adults with hypercholesterolaemia, reports a new meta-analysis.

Evolocumab added to high-intensity statins safely lowers LDL-C levels in acute ACS patients

28 Nov 2019

The addition of evolocumab to high-intensity statin therapy is both well tolerated and effective in significantly reducing low-density lipoprotein cholesterol (LDL-C) levels in patients hospitalized for acute coronary syndromes (ACS), allowing most of them to achieve current recommended target levels, a study has shown.

In this randomized, double-blind, placebo-controlled trial, the investigators analysed 308 patients hospitalized for ACS with elevated LDL-C levels (≥1.8 mmol/l on high-intensity statin for at least 4 weeks; ≥2.3 mmol/l on low- or moderate-intensity statin; or ≥3.2 mmol/l on no stable dose of statin). They randomized patients 1:1 to receive either subcutaneous evolocumab 420 mg or matching placebo, administered in-hospital and after 4 weeks, in addition to atorvastatin 40 mg.

The percentage change in calculated LDL-C from baseline to 8 weeks was the primary endpoint.

Of the patients, majority (78.2 percent) had not received statin treatment. At week 8, mean LDL-C levels decreased from 3.61 to 0.79 mmol/l in the evolocumab group and from 3.42 to 2.06 mmol/l in the placebo group, with a –40.7-percent (95 percent confidence interval, –45.2 to –36.2; p<0.001) difference in mean percentage change from baseline.

Significantly more patients in the evolocumab group compared with the placebo group achieved LDL-C levels <1.8 mmol/l at week 8 (95.7 percent vs 37.6 percent). Moreover, adverse events and centrally adjudicated cardiovascular events were comparable in both treatment arms.

Current guidelines recommend in-hospital initiation of high-intensity statin therapy in patients with ACS, but LDL-C target levels are usually not reached, according to the investigators.

Evolocumab is a rapidly acting and potent LDL-C–lowering drug.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
29 Mar 2020
Targeting a low-density lipoprotein cholesterol level <70 mg/dL following an ischaemic stroke of atherosclerotic origin helps to avoid one in four subsequent major vascular events without increasing the risk of intracranial haemorrhage over about 5 years of follow-up, according to data from the Treat Stroke to Target trial.
Pearl Toh, 12 Sep 2020
Early initiation of rhythm-control therapy led to a significantly reduced risk of major adverse cardiovascular (CV) outcomes compared with usual care (typically rate control) in patients with newly diagnosed atrial fibrillation (AF) at risk of stroke, reveals the EAST-AFNET 4* trial presented at ESC 2020.
01 Feb 2020
High-intensity statin therapy appears to be seeing increased use in patients with acute coronary syndrome and leads to better lipid control, according to a recent Thailand study.
18 Apr 2020
Statins appear to be useful as a primary prevention treatment in older adults with hypercholesterolaemia, reports a new meta-analysis.